Jankov Mirko R, Iseli Hans Peter, Bueeler Michael, Schor Paulo, Seiler Theo, Mrochen Michael
Milos Clinic Eye Hospital, Belgrade, Serbia and Montenegro.
J Refract Surg. 2006 May;22(5):472-81. doi: 10.3928/1081-597X-20060501-09.
To investigate the impact of phenylephrine and cyclopentolate on wavefront refraction and fourth order spherical aberration C12.
This cohort study comprised 151 eyes with sphere up to -10.00 diopters (D) and cylinder -3.75 D. Aberrometry was performed using the ALLEGRO WAVE (WaveLight Laser Technologies AG, Erlangen, Germany) after instillation of phenylephrine 5% yielding objective phenylephrine refraction in accommodated steady-state, as well as after cyclopentolate 0.5% providing objective cyclopentolate refraction in non-accommodated state. Accommodation target fogging was turned off. Wavefront aberrations were expressed by Zernike expansion up to the sixth order, and paraxial curvature matching with Taylor series was used to calculate objective wavefront sphere.
Objective wavefront sphere was not influenced by pupil size. Eyes showed substantial accommodation after phenylephrine with a myopic shift of -0.66 D comparing objective to subjective manifest sphere (r=0.942, P<.001). Cycloplegic eyes behaved like a model eye, with a difference of -0.08 D between objective and subjective cycloplegic sphere (r=0.976, P<.001). C12 increased ten-fold from 4.0- to 7.0-mm pupil size, keeping the same sign. Comparing cyclopentolate with phenylephrine, the sign of C12 changed in a positive direction by an average +0.124 +/- 0.109 microm (range: -0.052 to +0.632 microm) at 7.0 mm, whereas the total higher order aberrations changed very little. A good correlation was found between C12 and the change in objective wavefront sphere between cyclopentolate and phenylephrine (r=0.75, P<.001).
Fogging of the accommodation target should be used for wavefront measurements. Weaker cycloplegic agents, such as tropicamide, may be used to ensure relaxed but not completely paralyzed accommodation, which would yield "manifest" aberration values close to the natural resting state.
研究去氧肾上腺素和环喷托酯对波前像差和四阶球差C12的影响。
这项队列研究纳入了151只眼睛,球镜度数最高达-10.00屈光度(D),柱镜度数为-3.75 D。使用ALLEGRO WAVE(德国埃尔朗根的WaveLight激光技术公司)进行像差测量,在滴入5%去氧肾上腺素后获得调节稳态下的客观去氧肾上腺素验光结果,以及在滴入0.5%环喷托酯后获得非调节状态下的客观环喷托酯验光结果。调节目标雾视关闭。波前像差通过泽尼克展开式表示至六阶,并使用与泰勒级数匹配的近轴曲率来计算客观波前球镜度数。
客观波前球镜度数不受瞳孔大小影响。滴入去氧肾上腺素后眼睛出现明显调节,客观与主观显验光球镜度数相比近视漂移-0.66 D(r = 0.942,P <.001)。睫状肌麻痹的眼睛表现类似模型眼,客观与主观睫状肌麻痹球镜度数相差-0.08 D(r = 0.976,P <.001)。C12在瞳孔直径从4.0毫米增加到7.0毫米时增加了10倍,符号保持不变。在7.0毫米时,将环喷托酯与去氧肾上腺素相比,C12的符号向正方向平均改变+0.124±0.109微米(范围:-0.052至+0.632微米),而总高阶像差变化很小。C12与环喷托酯和去氧肾上腺素之间客观波前球镜度数的变化具有良好相关性(r = 0.75,P <.001)。
波前测量应采用调节目标雾视。可以使用较弱的睫状肌麻痹剂,如托吡卡胺,以确保调节放松但并非完全麻痹,这将产生接近自然静息状态的“显”像差值。